Lupin recalls eye drops from US market
Indian pharma company Lupin is recalling its conjunctivitis solution in the US market. The recall is classified class-III recall.
The recalled quantity is around 43,860 bottles of Moxifloxacin Ophthalmic solution. It is used in the treatment of bacterial conjunctivitis. It is a common type of pink eye, caused by bacteria that infect the eye through various sources of contamination. The bacteria can be spread through means of contact or exposure to contaminated surfaces. Around 6 million people are annually affected by conjunctivitis in the US. The US drug regulator, USFDA, has classified the recall as a class - III which is a situation in which exposure or consumption of the product is not likely to cause adverse health consequences.
According to USFDA, the product was distributed by five wholesalers, six drug chains, four mail order pharmacies and supermarkets.
Lupin is engaged in developing and delivering branded and generic formulations. It also produces biotechnology products and APIs, globally.
At 2:10 pm stock was trading at per share price of Rs. 773, marginally high by 0.38 per cent from the previous close. The benchmark index BSE Sensex showed a flattish negative trend, down by 22 points at 35,875.84.